ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO261

Cancer Status and Mortality in Older Hemodialysis Patients: Data from a Korean Society of Geriatric Nephrology Retrospective Cohort

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Kang, Seongmin, University of Ulsan, Ulsan, Korea (the Republic of)
  • Hong, Yu Ah, Catholic University of Korea Daejeon St Mary's Hospital, Daejeon, Korea (the Republic of)
  • Park, Woo Yeong, Keimyung University Dongsan Medical Center, Daegu, Korea (the Republic of)
  • Cho, Jang-Hee, Kyungpook National University Hospital, Daegu, Korea (the Republic of)
  • Sun, In O, Presbyterian Medical Center, Jeonju, Jeollabuk-do , Korea (the Republic of)
  • Hwang, Won Min, Konyang University Hospital, Daejeon, Korea (the Republic of)
  • Kwon, Soon hyo, Soonchunhyang University Hospital, Yongsan-gu, Seoul, Korea (the Republic of)
  • Yoo, Kyung Don, University of Ulsan, Ulsan, Korea (the Republic of)

Our study probed the correlation between cancer presence and mortality rates in elderly patients on hemodialysis, a link that is currently underexplored despite established associations between cancer, age, and chronic kidney disease (CKD).


We conducted a retrospective, multicenter cohort study through the Korean Society of Geriatric Nephrology. This study encompassed 2,085 patients aged 70 or above who commenced hemodialysis from 2010 to 2017. We employed the Kaplan-Meier survival estimator and Cox proportional hazards regression analysis to assess all-cause mortality.


Among our cohort, 262 patients (12.6%) had a cancer history, while 55 patients (2.6%) were managing active cancer. Over a median follow-up period of 3.2 years, 1,357 deaths (65.1%) occurred. The active cancer group revealed significantly higher all-cause mortality in comparison to those with a cancer history or no cancer (85.5% vs 68.3% vs 64.0%; p<0.002). Kaplan-Meier analysis underscored this mortality disparity among the groups (p < 0.001, log-rank test). Further, the multivariate Cox regression analysis, post-adjustment for clinical variables, evidenced a strong correlation between active cancer and all-cause mortality (HR:1.89; 95%CI: 1.36–2.64; p < 0.001). However, a history of cancer did not significantly raise overall mortality (HR:1.07; 95%CI: 0.90–1.28; p = 0.448).


Elderly patients on hemodialysis with active cancer demonstrated a higher mortality rate compared to those with a history of cancer or no cancer. Interestingly, cancer survivors exhibited a mortality risk akin to those never diagnosed with cancer. Thus, elderly cancer survivors may be viable candidates for dialysis.

Pairwise log rank test showed all between-group comparisons significant.